AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02170597
Drug: BIBR 1048 MS HPMC capsule
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01180062
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
Trial: NCT01180062
Drug: Latanoprost SR insert
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
Trial: NCT02170597
Drug: BIBR 1048 MS gelatine capsule
RxNorm normalized name: Gelatine
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01927874
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10ml 0.5% bupivacaine.
Trial: NCT01927874
Drug: 10 mg of hyperbaric 0.5% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal punction and injection of local anesthetic
Trial: NCT01678911
Drug: Gralise
RxNorm normalized name: Gralise
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication).
Trial: NCT01984177
Drug: Corticotropin-Releasing Hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
Trial: NCT04649060
Drug: Melflufen
RxNorm normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder for solution for i.v. infusion
Trial: NCT04649060
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets
Trial: NCT04649060
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for s.c. injection
Trial: NCT03137290
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
Trial: NCT03137290
Drug: Sugammadex Sodium
RxNorm normalized name: Sugammadex sodium
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
Trial: NCT02866552
Drug: Stromal Vascular fraction
RxNorm normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01427686
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
Trial: NCT00772291
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin 150-600mg/day during 8 weeks
Trial: NCT00256191
Drug: TPI 287 Injection
RxNorm normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00965042
Drug: Ceftobiprole
RxNorm normalized name: Ceftobiprole
DrugBank: Ceftobiprole (DB04918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
Trial: NCT01619423
Drug: PledOx (2 µmol/kg)
RxNorm normalized name: Pledox
DrugBank: Calmangafodipir (DB18398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
Trial: NCT01619423
Drug: PledOx (5 µmol/kg)
RxNorm normalized name: Pledox
DrugBank: Calmangafodipir (DB18398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
Trial: NCT01619423
Drug: PledOx (10 µmol/kg)
RxNorm normalized name: Pledox
DrugBank: Calmangafodipir (DB18398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
Trial: NCT00113984
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00961233
Drug: inhaled/swallowed budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: medication will be nebulized and then swallowed
Trial: NCT00961233
Drug: viscous/swallowed budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: viscous suspension of budesonide will be swallowed
Trial: NCT01007097
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
Trial: NCT01007097
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
Trial: NCT01007097
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
Trial: NCT01007097
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Trial: NCT01007097
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Trial: NCT01007097
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
Trial: NCT00904644
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
Trial: NCT03266965
Drug: Carbidopa
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
Trial: NCT04343963
Drug: Pyridostigmine Bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 60mg tablet P.O. once per day for 14 days
Trial: NCT00138580
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00851747
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Trial: NCT03431428
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
Trial: NCT02321800
Drug: Cefiderocol
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Trial: NCT02321800
Drug: Imipenem/cilastatin
RxNorm normalized name: imipenem/cilastatin/relebactam
DrugBank: Cilastatin (DB01597)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Trial: NCT00120835
Drug: valopicitabine
RxNorm normalized name: Valtorcitabine
DrugBank: Valopicitabine (DB13920)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00120835
Drug: pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01854710
Drug: ADASUVE 10 mg 2 doses 2 hours apart
RxNorm normalized name: Adasuve
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine 10 mg 2 doses 2 hours apart
Trial: NCT01854710
Drug: Oral moxifloxacin 400 mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin 400 mg single dose
Trial: NCT03053284
Drug: Pasireotide 0.6Mg Solution for Injection
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pasireotide 0.6Mg Solution for Injection will be given once per study visit
Trial: NCT03053284
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline Solution injection will be given once per study visit
Trial: NCT00982878
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg twice daily
Trial: NCT03951571
Drug: Anlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
Trial: NCT02215512
Drug: RRx-001 + WBRT
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
Trial: NCT02407353
Drug: PF-06648671
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
Trial: NCT00967135
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg oral dose of pregabalin twice daily for 5 consecutive days.
Trial: NCT02120677
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
Trial: NCT00064831
Drug: Black Cohosh Extract (BCE)
RxNorm normalized name: BLACK COHOSH EXTRACT
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03924401
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
Trial: NCT00299988
Drug: Intravenous Immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00834444
Drug: Famciclovir 500 mg Tablets
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x 500 mg, single-dose fasting
Trial: NCT01262001
Drug: FG-3019
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
Trial: NCT01262001
Drug: FG-3019
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
Trial: NCT03679091
Drug: low-dose ticagrelor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
Trial: NCT03679091
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
Trial: NCT02121067
Drug: Levonorgestrel Intrauterine System (LNG-IUS)
RxNorm normalized name: levonorgestrel Intrauterine System
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
Trial: NCT04418167
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib capsules for oral administration
Trial: NCT02890069
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02890069
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02817100
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
Trial: NCT03167411
Drug: Bexagliflozin
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexagliflozin tablets, 20 mg
Trial: NCT03167411
Drug: Exenatide Injection
RxNorm normalized name: exenatide Injection
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
Trial: NCT01055535
Drug: Microplasmin
RxNorm normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 125 µg intravitreal injection
Trial: NCT03885778
Drug: Besifovir dipivoxil
RxNorm normalized name: Besifovir dipivoxil
DrugBank: Besifovir dipivoxil (DB05020)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg Besifovir dipivoxil, single dose, oral
Trial: NCT01385215
Drug: Fluzone
RxNorm normalized name: Fluzone
DrugBank: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (DB10791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml/15 micrograms
Trial: NCT01385215
Drug: Fluzone
RxNorm normalized name: Fluzone
DrugBank: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (DB10791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml/60 micrograms
Trial: NCT00456560
Drug: AV650
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00456560
Drug: Fluvoxamine
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00456560
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02273492
Drug: Asasantin ER
RxNorm normalized name: Afsantin
DrugBank: Wormwood (DB14291)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02936830
Drug: 5% Sodium Fluoride Varnish
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% sodium fluoride varnish applied on the dentin by the dentist
Trial: NCT02936830
Drug: Glycerol
RxNorm normalized name: Glycerol
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycerol with water in a 1: 1 ratio
Trial: NCT03962010
Drug: GX-G6
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long acting anti-diabetic drug
Trial: NCT03962010
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT00669162
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/m2 IV weekly for 7 weeks
Trial: NCT04665830
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: treated patients with evolocumab for high cholesterol
Trial: NCT03208231
Drug: Combination Antiretroviral Therapy (cART)
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All infants received non-study provided cART selected by their primary care provider and supplied through non-study sources (i.e., cART not provided through the study).
Trial: NCT02331563
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ultrasound guided transvers abdominis plane block
Trial: NCT02331563
Drug: 0.25 % bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound guided transvers abdominis plane block
Trial: NCT04983160
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol
Trial: NCT01634139
Drug: Tiotropium low dose QD
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 actuations once daily in the evening
Trial: NCT01634139
Drug: Tiotropium high dose QD
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 actuations once daily in the evening